Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + SBRT in Advanced or Metastatic Sarcoma
NCT05488366Phase 1Active, not recruiting
- Sponsor
- University of California, Irvine
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in soft tissue sarcoma (STS) (2 arms), sponsored by University of California, Irvine. Primary endpoint: Feasibility, measured as the number of patients completing treatment up to 3 years. Started Aug 2022; status: active, not recruiting.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05488366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488366.